Mrowietz Ulrich, Reich Kristian
Psoriasis-Zentrum, Abteilung Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Schittenhelmstr. 7, 24105 Kiel, Germany.
Dtsch Arztebl Int. 2009 Jan;106(1-2):11-8, quiz 19. doi: 10.3238/arztebl.2009.0011. Epub 2009 Jan 5.
Psoriasis is one of the most prevalent chronic inflammatory diseases, affecting approximately 2 million people in Germany.
Selective literature review taking into account the German S1 and S3 guidelines for the treatment of this condition.
Psoriasis is a very troublesome disease with a high economic impact. The disease often persists for life, and the patient has an increased risk of cardiovascular diseases and their complications. One out of five patients develops psoriatic arthritis. The clinical picture of psoriasis is highly variable with regard to lesional characteristics and the severity of disease. To improve the management of psoriasis the guidelines must be followed and all appropriate topical and systemic treatment options must be tried, with clearly defined treatment goals. The spectrum of established systemic treatments for psoriasis has been extended by the biologics. These can be used to achieve a good skin status and a clear-cut improvement in quality of life even in patients who do not--or no longer--respond adequately to conventional therapies.
银屑病是最常见的慢性炎症性疾病之一，在德国约有200万人受其影响。
参考德国关于该疾病治疗的S1和S3指南进行选择性文献综述。
银屑病是一种非常棘手的疾病，具有很高的经济影响。该疾病常持续终生，患者患心血管疾病及其并发症的风险增加。五分之一的患者会发展为银屑病关节炎。银屑病的临床表现因皮损特征和疾病严重程度而异。为改善银屑病的管理，必须遵循指南并尝试所有适当的局部和全身治疗方案，同时要有明确的治疗目标。生物制剂扩大了已确立的银屑病全身治疗的范围。即使对于那些对传统疗法无充分反应或不再有充分反应的患者，这些生物制剂也可用于实现良好的皮肤状态并显著改善生活质量。
